Gain Therapeutics Inc.
GANX | NASDAQ
$1.87
+$0.03 (+1.63%)
Sep 22, 2026, 1:29 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 55.18K | 140.11K | 164.99K | 28.88K |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | 55.18K | 140.11K | 164.99K | 28.88K |
Operating Income | -18.71M | -20.35M | -22.25M | -17.78M | -13.83M | -3.48M |
Interest Income | 244.39K | 357.1K | 494.23K | 375.36K | 12.5K | 3.64K |
Pretax Income | -19.3M | -19.87M | -22.19M | -17.5M | -13.89M | -3.57M |
Net Income | -20.16M | -20.41M | -22.27M | -17.59M | -13.89M | -3.58M |
Selling & General & Admin | 8.5M | 9.56M | 10.79M | 9.54M | 6.83M | 1.25M |
Research & Development | 10.21M | 10.79M | 11.52M | 8.38M | 7.16M | 2.26M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 18.71M | 20.35M | 22.31M | 17.92M | 13.99M | 3.51M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 18.71M | 20.35M | 22.31M | 17.92M | 13.99M | 3.51M |
Income Tax Expense | 861.12K | 536.82K | 79.28K | 92.98K | 4.01K | 5.39K |
Shares Outstanding (Basic) | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M | 11.88M |
Shares Outstanding (Diluted) | 32.97M | 22.88M | 13.01M | 11.88M | 10.17M | 11.88M |
EPS (Basic) | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -0.30 |
EPS (Diluted) | -0.61 | -0.89 | -1.71 | -1.48 | -1.37 | -0.30 |
EBITDA | -19.21M | -19.79M | -22.1M | -17.43M | -13.87M | -3.47M |
EBIT | -19.3M | -19.87M | -22.19M | -17.5M | -13.89M | -3.48M |
Depreciation & Amortization | 94.05K | 84.07K | 83.58K | 64.17K | 15.48K | 9.59K |
Add to Watchlist
Select watchlists to add or remove GANX